Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.38 |
| ▸ | VNN1 | O95497 | 4/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27922982 | 0.82 | HCAR2 (0.41) | HCAR2VNN1CYP19A1 | |
| SCHEMBL27405232 | 0.80 | PTGS2 (0.45) | HCAR2 | |
| SCHEMBL1484347 | 0.78 | EPHX1 (0.44) | HCAR2VNN1CYP19A1 | |
| SCHEMBL11838106 | 0.74 | CYP19A1 (0.47) | CYP19A1 | |
| SCHEMBL1808418 | 0.71 | HCAR2 (0.34) | HCAR2CYP19A1 | |
| SCHEMBL8922394 | 0.71 | AKR1C3 (0.35) | HCAR2 | |
| SCHEMBL27485847 | 0.71 | APP (0.42) | HCAR2VNN1CYP19A1 | |
| SCHEMBL24683919 | 0.69 | — | — | |
| SCHEMBL18427397 | 0.69 | — | — | |
| SCHEMBL6980862 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7935700-B2 | Morpholine compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-05-03 | — | — | US | disclosed |
| US-20070265257-A1 | Morpholine Compound | MITSUBISHI PHARMA CORPORATION (JP) | 2007-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265257-A1 | Morpholine Compound | CCR3, CCR1, CCR4 | HCAR2 967/4885VNN1 4538/4885CYP19A1 2951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.